Generic and new drug application supplement work related to COVID-19 jumped during the third quarter of fiscal year 2021, although pandemic-related full ANDA approvals were on the decline.
The latest data on FDA efforts to approve applications related to the coronavirus pandemic indicated that ANDA supplement and NDA and BLA manufacturing supplement approvals increased 44% in FY 2021 through the third quarter